Foundation Fighting Blindness Retinal Degeneration Fund sold $7.4M of IRD
director, other at Opus Genetics, Inc.. 1,700,000 shares at an average of $4.35, traded May 18, 2026, filed May 20, 2026.
Score components
- +15RoleDirector
- +25Trade size$7.4M at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.3%, 3m -8.3%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002042266-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 18, 2026 | SOpen-market sale Common Stock | -1,700,000 | $4.35 | $7.4M | 3,792,171 | May 20, 2026 |
Related signals
Other insiders at Opus Genetics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRDsell Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund director, other | $2.8M 556,000 shares | -15% | |
| 13Weak | Opus Genetics, Inc. | Robert E. Gagnon Chief Financial Officer | $127k 28,000 shares | -5% | |
| 43Moderate | Opus Genetics, Inc. | Robert E. Gagnon Chief Financial Officer | $41k 7,842 shares | -1% | |
| 36Weak | Opus Genetics, Inc. | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | $39k 7,542 shares | -1% | |
| 47Moderate | Opus Genetics, Inc. | George Magrath Chief Executive Officer | $50k 9,511 shares | -1% | |
| 30Weak | Opus Genetics, Inc. | Rabourn Amy Zaremba Head of Fin. Quality Assurance | $8,540 1,641 shares | -1% | |
| 35Weak | Opus Genetics, Inc. | Joseph K Schachle Chief Operating Officer | $25k 4,697 shares | -2% | |
| 41Moderate | Opus Genetics, Inc. | Benjamin R Yerxa President | $39k 7,470 shares | -1% | |
| 30Weak | Opus Genetics, Inc. | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | $19k 3,719 shares | -1% | |
| 51Moderate | Opus Genetics, Inc. | George Magrath Chief Executive Officer | $127k 24,438 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.